Indoco Remedies has announced the launch of Fevindo, which is the company's Favipiravir tablet. The drug has been approved by Drugs Controller General of India (DCGI) in the treatment of COVID-19.

Share Market Live

NSE

Fevindo is one of the few players in the market with 400 mg strength, said Aditi Kare Panandikar, Managing Director of Indoco Remedies. It is the cheapest one available in the market today and a seven-day course costs Rs 2,100.

The company is looking at annual revenues of around Rs 100 crore from Fevindo.

Watch the video for more.